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Abstract
Platelet-derived growth factor B (PDGF-B) is a growth factor promoting and regulating cell migration, proliferation, and
differentiation, involved in both developmental processes and in maintaining tissue homeostasis under strict regulation. What
are the implications of prolonged or uncontrolled growth factor signaling in vivo, and when does a growth factor such as
PDGF-B become an oncogene? Under experimental conditions, PDGF-B induces proliferation and causes tumor induction.
It is not known whether these tumors are strictly a PDGF-B-driven proliferation of cells or associated with secondary genetic
events such as acquired mutations or methylation-mediated gene silencing promoting neoplasia. If PDGF-B-driven tumori-
genesis was only cellular proliferation, associated changes in gene expression would thus be correlated with proliferation and
not associated with secondary events involved in tumorigenesis and neoplastic transformation such as cycle delay, DNA
damage response, and cell death. Changes in gene expression might be expected to be reversible, as is PDGF-B-driven
proliferation under normal circumstances. Since PDGF signaling is involved in oligodendrocyte progenitor cell differentiation
and maintenance, it is likely that PDGF-B stimulates proliferation of a pool of cells with that phenotype, and inhibition of
PDGF-B signaling would result in reduced expression of oligodendrocyte-associated genes. More importantly, inhibition of
PDGF signaling would be expected to result in reversion of genes induced by PDGF-B accompanied by a decrease in
proliferation. However, if PDGF-B-driven tumorigenesis is more than simply a proliferation of cells, inhibition of PDGF
signaling may not reverse gene expression or halt proliferation. These fundamental questions concerning PDGF-B as a
potential oncogene have not been resolved.
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Introduction
Platelet-derived growth factor B
Platelet-derived growth factor B (PDGF-B) was ﬁrstly
isolated as a protein produced by platelets that stim-
ulate DNA synthesis and growth of cells in culture,
hence the name (1). The physiological function of this
30-kDa protein was not yet known except for its
growth-promoting properties of cultured cells.
PDGF-B binds as a dimer to cell surface receptors,
upon which they are dimerized and phosphorylated.
The auto-phosphorylation activates the receptors and
enables phosphorylation of downstream targets by the
intracellular receptor kinase domain, resulting in a
signaling cascade, which ultimately promotes DNA
synthesis and cell division in concert. This
proliferation-promoting mechanism of growth factors
and their receptors is essential for cells to multiply
through embryogenesis and in a healthy organism.
PDGF-B is also important in initiating cytoskeletal
remodeling and cell motility in wound healing (2,3).
What are growth factors?
Both growth factors and oncogenes stimulate the
proliferation of cells. One deﬁnition of a growth factor
is ‘a naturally occurring substance capable of stimu-
lating cellular growth, proliferation, and cellular
differentiation’ (4). Perhaps an even better deﬁnition
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biological factors that are produced by the body to
control growth, division, and maturation‘ (5). How-
ever, not all proteins classiﬁed as growth factors
stimulate differentiation; some even promote dedif-
ferentiation, such as PDGF-B (6,7), and some have
dual roles stimulating proliferation and/or differenti-
ation depending on the context, tissue, and cell type.
Another example where a growth factor does not
promote differentiation is epidermal growth factor
(EGF), which stimulates proliferation of undifferen-
tiated cell types without promoting differentiation to
maintain a constant pool of stem cells in the brain
(8,9). EGF is also important in maintaining undiffer-
entiated pancreatic cells, and upon its removal cells
differentiate (10). In the central nervous system,
PDGF-B initially stimulates differentiation of undif-
ferentiated glia to progenitor states, subsequently
maintaining a pool of oligodendrocyte progenitor cells
without promoting further differentiation (11–16).
Growth factors stimulate differentiation, dedifferen-
tiation, or maintenance of differentiation status in a
context-dependent way that does not always end in
terminal differentiation.
Growth factor-regulated differentiation
Under normal circumstances, growth factor-
driven differentiation results in differentiation
accompanied by cell cycle exit. In most cases differ-
entiation is terminal. However, there are experimen-
tal studies demonstrating plasticity in differentiation,
where growth factors induce reversion to or maintain
a less differentiated phenotype. PDGF-B can induce
dedifferentiation of astrocytes into oligodendrocyte
progenitor cells (6). Growth factors can also main-
tain less differentiated cells. In mammary tissue
forced expression of TGF-beta inhibits growth and
differentiation without any signs of inducing neopla-
sia, indicating that this growth factor is important in
maintaining a pool of undifferentiated progenitor
cells of the mammary tissue. This process of main-
taining tissue homeostasis while preventing devel-
opment of the mammary gland is also reversible
where removal of the growth factor results in
differentiation (17). This ﬂexibility in growth
factor-driven proliferation (and to some extent dif-
ferentiation) indicates that arrested cells or termi-
nally differentiated cells may still be susceptible to
exogenous growth factor stimulation. Even differ-
entiatedmouse (18) and humancells(19–21) can be
reprogrammed to dedifferentiate. However, it is
likely that additional events are required for a
growth factor to induce a malignant transformation
and ultimately cancer.
Roles of normal cellular proliferation and cell
division
PDGF-B is a growth factor in that it regulates cellular
growth, i.e. cell division. Indirectly that means the
duplication of the DNA content of a cell co-
ordinated with segregation of the chromosomes, pro-
duction of cellular components and structural
elements, and physical division of the cell into two
daughter cells. Cell division can be symmetric or
asymmetric, generating two identical daughter cells
or two cells of different fate (22). The ratio of sym-
metric and asymmetric cell division can regulate the
amount of a speciﬁc cell type or stem cell and their
differentiated progeny to maintain tissue homeostasis.
It is believed that stem cells self-renew by asymmetric
division, generating one stem cell and one cell com-
mitted to differentiation. Cell division occurs natu-
rally at a higher frequency during embryogenesis to
build up tissue and organs. A temporary increase in
growth factors promoting increased proliferation and/
or differentiation to repair damage to tissue due to
injury is also a normal function. Throughout life a
constant pool of stem cells is maintained by asym-
metric and symmetric proliferation. In case of injury
or disease, stem cells can have a burst of proliferation
to produce more differentiated cells in order to
replace damaged or dead ones. Cellular proliferation
also exists in tissues to make up for normal loss of
cells; in highly proliferative tissues such as skin and
mucosal membranes or bone-marrow this is a rapid
process, and in other tissues such as brain or kidney it
is almost negligible. Proliferation occurring under the
aforementioned circumstances is normal and beneﬁ-
cial. These proliferative cues are under strict control
of cellular mechanisms in place to prevent cells from
inappropriate division generating a larger pool of cells
than necessary or vice versa.
Control of normal growth factor-driven
proliferation
If production of cells exceeds what is necessary for a
healthy organism it could be pathological. Having too
many cells is deleterious to any organism since they
require oxygen and nutrients. Excessive cells also
need physical space, which can damage or impair
the function of neighboring cells and the entire organ.
These cells can also negatively inﬂuence surrounding
cells by signaling through secreted factors or by direct
cell–cell interactions. Such proliferations of cells may
or may not be limited to cancer but is under any
circumstance a pathological condition. In a normal
cell or tissue, growth factor signaling most commonly
leads to proliferation and ultimately differentiation
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tumor barrier. One of the things that distinguish
normal growth factor-driven cell proliferation from
cancer is that cancerous cells evade senescence and
continue to grow independently, possibly due to
acquiring other genetic changes that promote cellular
growth and inhibit senescence and/or apoptosis.
Growth factor-driven proliferation is reversible in a
normal cell: upon removal or inhibition of growth
factor signaling a normal cell would arrest or
undergo apoptosis (23–30). PDGF-B is known for
its role in establishing the oligodendrocyte glial
lineage and sustaining a pool of oligodendrocyte
progenitor cells by signaling through the PDGF
receptor alpha (PDGFRA). Infusion of PDGF-A in
the ventricular system for several days can cause
expansion of cells expressing the PDGFRA and
induction of some glioma characteristics. However,
this expansion is reversible upon removal of PDGF-A,
indicating that this effect is a growth factor-driven
proliferation of a subtype of cells responsive to PDGF
signaling (31).
Prolonged or abnormal growth factor signaling
A direct consequence of proliferation is replicative
stress. In addition, by-products of cellular metabolism
accompanying proliferation, such as free radicals,
promote errors in DNA. The replication process is
inherently error-prone, and while most errors are
corrected it is estimated that uncorrected errors
that persist could range from 1  10
-4 to 1  10
-6
mutations per gamete for a given gene. There are
paramount proof-reading functions of the cell that
detect and repair errors. In case of proof-
reading failure, other programs are activated to elim-
inate cells with DNA copy error in order to protect the
integrity of the organism. However, this is not a 100%
fail-proof system, which means that proliferation can
result in cells with DNA errors, a risk increasing with
increased proliferative rate. If a speciﬁc DNA muta-
tion affects a gene involved in cell proliferation or
survival, this could through positive selection result in
a rapidly increasing pool of abnormal cells, and
increased proliferation could secondarily lead to accu-
mulation of more DNA damage.
What is cancer if not abnormal proliferation of
abnormal cells? In fact, 90% of cancers arise in
epithelial surfaces from cells with a high proliferative
rate (32). According to the National Cancer Institute
(NCI), ‘cancer is a term used for diseases in which
abnormal cells divide without control and are able to
invade other tissues’. An oncogene could be deﬁned
as a factor that induces uncontrolled cell division and
invasive ability. So if the amount of a growth factor is
high enough could it lead to cancer, hence function as
an oncogene? Growth factor-induced proliferation
leading to an increasing number of cells would not
mean that these cells are able to invade other tissues.
However, considering that replicative stress leads to
errors in DNA, where further growth-promoting
mutations will be selected for, elevated growth factor
signaling could eventually lead to cancer through
secondary accumulated mutations involving genes
that regulate contact inhibition and migration. These
steps are described as classical hallmarks of cancer
(33), and oncogenic stress causing chromosomal
instability and evoking DNA damage response is
well established (34,35).
There is compelling evidence that replicative stress
caused by growth factors can ultimately result in
secondary genetic changes leading to cancer progres-
sion. Preneoplastic lesions of skin, urinary, lung,
colon, and breast cancer already have activated
DNA damage check-points (34,36). In a model of
melanoma, skin grafts were made hyperplastic by
addition of growth factors, such as basic ﬁbroblast
growth factor, stem cell factor, and endothelin-3, over
4 weeks. These hyperplasias had activated DNA
damage response in terms of 53BP1 foci, phosphor-
ylated histone H2AX and Chk2, increased p53 levels,
and apoptosis likely as a result of DNA damage
response (36). PDGF-B over-expression has also
been shown to induce DNA damage response, geno-
mic instability and ploidy in glial cells, and hyper-
plastic lesions of the brain and subsequent gliomas
(37). Over-expression of cyclin E, common in cancer
and rapidly cycling cells, results in increases in Ser
15-phosphorylated p53, g-H2AX, and Ser 966-phos-
phorylated cohesin SMC1, which are all targets of the
DNA damage response kinases ATM and ATR (34).
This points to the conclusion that over-expression of
PDGF-B could cause replicative stress and ultimately
result in tumorigenesis.
PDGF as an oncogene
Studies of oncogenic retroviruses have identiﬁed
numerous transforming genes with structural resem-
blance to human growth factors, leading to the
hypothesis that human cancers may be caused by
growth factors (38). In 1983 it was found that the
active domain of PDGF-B shared an almost identical
structure with the cancer-causing gene of Simian
sarcoma virus, v-sis (39–41) and that there were
multiple PDGF homologues (42,43). Further,
many cancers harbor genetic alterations in growth
factor-encoding genes (44–46), and brain tumors
express the c-sis chain (PDGF-B) (47). Are
these alterations cancer-causing or a result of
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positively selected for? In support, in a family with a
germline missense mutation of PDGFRA (G2675T)
the mutated allele segregated with gastrointestinal
stromal tumor (GIST) incidence (48). Another
PDGFRA germline mutation (V561D and Y555C)
is also associated with sporadic GIST (49,50). Finally,
in the case of gliomas, there have been at least two
alterations identiﬁed in the PDGFR gene that lead to
constitutive activation of the encoded protein (51).
Experimental studies have shown that PDGF can be
causal in tumor formation in vivo. Retrovirus contain-
ing PDGF-B was introduced into newborn mice (52),
causing ﬁbrosarcoma, and later studies have conﬁrmed
that over-expression of PDGF-B can cause a variety of
neoplasms, in particular brain tumors (53). One study
indicated that there are additional events required for
tumor progression upon PDGF-B stimulation (54),
and concomitant loss of tumor suppressor genes
increases malignancy in two viral models of PDGF-
B-induced brain tumors (55,56). Additional events
secondary to PDGF signaling might explain why
growth factor inhibitors such as imatinib have had
limited success in clinical trials so far (57,58); selection
of patients with PDGFRA-positive glioblastomas did
not confer any beneﬁt of this treatment (59). Another
possible reason why inhibitors of PDGF have had
limited clinical success could be that chronic PDGF
signaling leads to DNA methylation, which is not
reversed by blocking receptor activity.
Classical oncogenes, like K-Ras, have aberrant sig-
naling due to mutations rendering them more active.
The most common form of mutated K-Ras, G12D,
can induce and drive tumorigenesis, but in this case
tumors are dependent on the oncogene and upon
withdrawal they regress (60). This holds true for other
oncogenes as well, such as H-Ras
V12G (61), MYC
(62), and Bcr-Abl (63). However, when PDGF-B acts
as an oncogene it is in its native form but is produced
at higher levels, maybe in the wrong cell or at the
wrong time. In this case the oncogenic effect of PDGF
is in regulation or dysregulation of production of this
otherwise normal protein. Removal of the signal
might be insufﬁcient, as indicated by the lack of effect
of inhibitors of PDGF signaling, since neoplastic cells
may have developed beyond dependence of PDGF-B
signaling by acquiring other genetic or epigenetic
modiﬁcations as a result of replicative stress. It is
also possible that chronic PDGF-A stimulation
induces glioma-like lesions that are reversible upon
removal of PDGF-A (31) only if there are no addi-
tional events occurring. One study has demonstrated
how PTK787-mediated inhibition of PDGF signaling
in PDGF-B-induced gliomas results in a markedly
reduced proliferation without elimination of tumors,
indicating that these tumors are dependent on PDGF
signaling to maintain proliferative capacity while inhi-
bition does not eliminate tumors (64). The mecha-
nism by which PDGF-B induces glioma, and if it is
reversible, has yet to be determined.
Is it possible to distinguish a growth factor from
an oncogene?
Perhaps one could deﬁne an oncogene as something
that induces proliferation of cells beyond what is
reversible upon removal of that factor due to second-
ary events. Secondary events include genetic changes
such as mutations, ampliﬁcations or deletions, and/
or methylation-mediated gene silencing, resulting in
changes of gene expression. A ‘normal’ proliferation
induced by a growth factor is reversible, where
removal of the growth factor results in halted prolif-
eration and reversion of gene expression changes
associated with growth factor-driven proliferation.
Is PDGF-B a growth factor, i.e. is PDGF-B-driven
proliferation and glioma formation reversible, or is
PDGF-B an oncogene?
One way of addressing this question experimentally
would be to determine which changes in gene expres-
sion are induced by PDGF-B over-expression and if
there is any proof of replicative stress or DNA meth-
ylation caused by chronic PDGF-B stimulation that
could promote tumorigenesis. If PDGF-B is just a
growth factor, changes in gene expression between
PDGF-B-driven tumor cells and their normal coun-
terpart, oligodendrocyte progenitor cells (OPCs),
would be limited to genes involved in proliferation,
i.e. cell cycle and cell division. However, if chronic
PDGF-B stimulation causes replicative stress that
could result in secondary genetic effects driving
tumorigenesis, an increase in expression of genes
involved in cell cycle delay and arrest, DNA damage
response and possibly senescence or cell death would
be seen. PDGF-B-driven proliferation in a normal cell
is tightly regulated and reversible; upon growth factor
removal proliferation is halted. By inhibiting PDGF
signaling using a small molecule kinase receptor
inhibitor a benign PDGF-B-driven proliferation is
arrested and gene expression would return to that
of an unstimulated cell, while a cell turned neoplastic
would be less likely to respond. These experiments
could be done using an in-vivo system where PDGF-
B-driven proliferation is inhibited chemically and
gene expression compared between normal OPCs,
PDGF-B-stimulated cells, and cells treated with the
small molecule kinase inhibitor. An experiment of
that kind would answer the question if PDGF-B-
driven proliferation is reversible and what gene
expression changes are associated with PDGF-B.
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to study PDGF-B-driven tumorigenesis in vivo.B y
using this model it is possible to induce expression
of PDGF-B in speciﬁc subsets of glial cells in vivo by
retroviral-mediated gene transfer. The Nestin-
tva (Ntv-a) transgenic mice in an Ink4a-Arf
-/- Pten
ﬂ/ﬂ
background develop Olig2-positive glioblastomas
upon PDGF-B expression homologous to human glio-
blastomas of the proneural subtype with the same
histopathology, including pseudopalisading necrosis,
microvascular proliferation, and high mitotic activity
(65,66). This model also shares the genetic hallmarks
of human GBMs of proneural subtype where
PDGFRA, PTEN, and CDKN2A each are altered
in 10%–70% of cases (67). Tumors are believed to
originate from a glial progenitor cell and are almost
ubiquitously positive for the basic helix-loop-helix
transcription factor Olig2, which regulates the fate of
neural and glial progenitor cells and promotes differ-
entiation of the oligodendrocytic lineage. By combi-
ning the RCAS-TVA model with a reporter that would
allow isolation of Olig2-expressing cells for expression
analysis,one should beable todetermine ifthe changes
in expression that accompany oncogenic transforma-
tion of this cell population are reversed by blockade of
PDGFR signaling. If all the expression changes were
reversed by PDGFR blockade then one would argue
that the effect of PDGF in this context was a growth
factor. However, if only a minority or none of the
changes induced by PDGF-induced gliomagenesis
were reversed by PDGFR blockade one would then
argue that PDGF was acting as an oncogene.
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